iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
146 hedge funds and large institutions have $460M invested in iTeos Therapeutics in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 47 reducing their positions, and 25 closing their positions.
36% more call options, than puts
Call options by funds: $1.38M | Put options by funds: $1.01M
21% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.51% less ownership
Funds ownership: 100.73% → 97.22% (-3.5%)
5% less funds holding
Funds holding: 153 → 146 (-7)
6% less capital invested
Capital invested by funds: $489M → $460M (-$28.4M)
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.25M |
| 2 |
BlackRock
New York
|
+$3.09M |
| 3 |
Goldman Sachs
New York
|
+$2.93M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.44M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$7.21M |
| 2 |
Morgan Stanley
New York
|
-$5.51M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$5.32M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.74M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.54M |
ITOS Hedge Fund Activity: Q2 2023 in Review
146 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q2 2023, worth a combined $460M — down 5.8% from $489M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ITOS and 18 opened new positions — a net loss of 7 holders — while 47 trimmed existing stakes and 57 added.
The largest buyer was Millennium Management, adding an estimated $4.25M. The largest seller was JP Morgan Chase, cutting an estimated $7.21M.
- 146 institutional investors held iTeos Therapeutics (ITOS) as of Q2 2023, down from 153 in Q1 2023.
- Funds reported $460M of iTeos Therapeutics stock for Q2 2023, down 5.8% quarter-over-quarter.
- 18 funds opened new iTeos Therapeutics positions in Q2 2023 and 25 closed out, a net change of -7 holders.
- The largest iTeos Therapeutics buyer in Q2 2023 was Millennium Management, an estimated $4.25M added.
- The largest iTeos Therapeutics seller in Q2 2023 was JP Morgan Chase, an estimated $7.21M sold.
Based on aggregated 13F filings for Q2 2023.